HCM (HCM) Stock Price & Analysis
HCM (HCM) fell 2.03% to USD 10.63 as of June 10, 2026 at 01:00 UTC, according to Nexqual real-time market data.
HCM last closed at USD 10.85; the session ranged USD 10.43–10.89 on volume of 53,931 shares. Market capitalization is $1.83B, with a 52-week range of USD 10.43–19.5 (NMS). Source: Nexqual, June 10, 2026 at 01:00 UTC.
Key Statistics (as of June 10, 2026 at 01:00 UTC)
| Price | USD 10.63 |
|---|---|
| Change | ▼ 2.03% (down) |
| Previous Close | USD 10.85 |
| Open | USD 10.88 |
| Day Range | USD 10.43 – 10.89 |
| 52-Week Range | USD 10.43 – 19.5 |
| Volume | 53,931 shares |
| Market Cap | $1.83B |
| Exchange | NMS |
Technical Analysis (HCM)
Nexqual's technical model rates HCM "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 01:00 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 17.5 (oversold) |
| vs SMA50 | Below (USD 13.33) |
| MACD | -0.68 (negative) |
Analyst Ratings (HCM)
Wall Street analysts rate HCM "Buy" based on 15 analysts, with a mean price target of USD 22.84 (range USD 13.6–40.4), per Nexqual as of June 10, 2026 at 01:00 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 22.84 |
| High Target | USD 40.4 |
| Low Target | USD 13.6 |
| Buy / Hold / Sell | 11 / 3 / 0 |
Earnings (HCM)
Source: Nexqual, June 10, 2026 at 01:00 UTC.
Financials & Fundamentals (HCM)
| Total Revenue | $548.51M |
|---|---|
| Revenue Growth (YoY) | -16.50% |
| Gross Margin | +11.64% |
| Operating Margin | -13.16% |
| Profit Margin | +83.30% |
| ROE | +45.25% |
| Debt / Equity | 7.82 |
| Current Ratio | 4.96 |
| Total Cash | $1.37B |
| Total Debt | $97.89M |
| Free Cash Flow | $-54.01M |
Source: Nexqual, June 10, 2026 at 01:00 UTC.
Financial Health Score (HCM)
Nexqual rates HCM's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 01:00 UTC.
| Growth | Critical — Revenue -13% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Gross margin 12%, operating -13% |
| Balance Sheet | Strong — $1.37B cash vs $98M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$54M, burning cash |
| Efficiency | Strong — ROE 45%, ROA -1.6% |
Ownership (HCM)
| Insider Ownership | +0.01% |
|---|---|
| Institutional Ownership | +2.57% |
| Shares Outstanding | 171.95M |
| Float | 101.69M |
| Short % of Float | +0.21% |
Source: Nexqual, June 10, 2026 at 01:00 UTC.
Leadership (HCM)
HCM is led by Chig Fung Cheng BEc, CA (age 58), Acting CEO, CFO & Executive Director, per Nexqual as of June 10, 2026 at 01:00 UTC.
| Acting CEO, CFO & Executive Director | Chig Fung Cheng BEc, CA (age 58) |
|---|---|
| CEO, Chief Scientific Officer & Executive Director (Leave of Absence) | Wei-Guo Su B.Sc. (age 66) |
| Executive Vice President & Chief Technical Officer | Xinhui Hu (age 52) |
| Senior Vice President of Corporate Management & Communications | Kin Hung Lee (age 48) |
| Senior Vice President of Global Human Resources | Selina Zhang |
Major Backers & Investors (HCM)
Notable institutional backers of HCM include Schroder Investment Management Group, Aia Group Ltd, M&G Plc, according to Nexqual as of June 10, 2026 at 01:00 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Schroder Investment Management Group | 0.85% |
| Aia Group Ltd | 0.17% |
| M&G Plc | 0.15% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Allianz Asset Management GmbH | 0.48% |
| State Street | 0.21% |
| Amundi | 0.13% |
Source: Nexqual, June 10, 2026 at 01:00 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ZLAB | Zai Lab Limited | USD 16.65 | ▲ 0.18% |
| LEGN | Legend Biotech Corporation | USD 33.49 | ▲ 2.67% |
| GDS | GDS Holdings Limited | USD 36.11 | ▲ 6.21% |
| LIVN | LivaNova PLC | USD 77.17 | ▲ 6.65% |
| GRFS | Grifols, S.A. | USD 7.34 | ▼ 3.93% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:00 UTC. This page is informational and not investment advice.